Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
LAL-BR/2001: Study Treatment to Low Risk ALL
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 150
- Registration Number
- NCT00526175
- Locations
- 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸Hospital General de Alicante, Alicante, Spain
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00526409
- Locations
- 🇪🇸
Hospital Niño Jesús, Madrid, Spain
🇪🇸Hospital materno Infantil vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Infantil Carlos Haya, Málaga, Spain
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00526305
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸H.U. Virgen del Rocio, Sevilla, Spain
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2009-05-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 374
- Registration Number
- NCT00494897
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital general de Castellón, Castello, Castellón, Spain
🇪🇸Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2019-02-15
- Target Recruit Count
- 470
- Registration Number
- NCT00458848
- Locations
- 🇮🇹
Ospedale S. Donato, Arezzo, Italy
🇮🇹S.G. Moscati Hospital, Avellino, Italy
🇮🇹Ospedale Binaghi, Cagliari, Italy
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateDrug: vindesineRadiation: radiation therapy
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 4559
- Registration Number
- NCT00430118
- Locations
- 🇦🇹
LKH Leoben, Leoben, Austria
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch-Tisis, Austria
🇦🇹Universitaet Kinderklinik, Graz, Austria
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- Other: Laboratory Biomarker AnalysisDrug: CyclophosphamideDrug: AsparaginaseDrug: Daunorubicin HydrochlorideDrug: CytarabineDrug: MercaptopurineDrug: Leucovorin CalciumDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: MethotrexateDrug: NelarabineDrug: PrednisoneDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00381680
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1070
- Registration Number
- NCT00372593
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.